FDA Class II Recall: Teva Pharmaceuticals' Budesonide Extended-Release Tablets Fail Dissolution Specifications
Teva Pharmaceuticals USA, Inc. has initiated a Class II recall for 10,672 bottles of Budesonide Extended-Release Tablets 9mg due to failed dissolution specifications. This event, stemming from manufacturing at Actavis Laboratories FL, Inc., signals potential efficacy issues and mandates immediate review of supply chain resilience for procurement and regulatory teams reliant on Teva's generic corticosteroid products.
FDA Initiates Class II Recall for Teva's Budesonide Extended-Release Tablets
Teva Pharmaceuticals USA, Inc. has voluntarily initiated a Class II recall, identified as D-0275-2024, for specific lots of Budesonide Extended-Release Tablets 9mg. This critical regulatory action, reported to the FDA on February 7, 2024, stems from the product failing dissolution specifications. The recall specifically targets Lot # 100047273, with an expiration date of July 2025, encompassing 10,672 30-count bottles distributed nationwide. For procurement directors and supply chain VPs, this means an immediate need to quarantine affected inventory and assess the continuity of supply for this orally administered corticosteroid. A dissolution failure indicates that the active pharmaceutical ingredient, Budesonide, may not be released from the tablet at the intended rate or extent, potentially compromising therapeutic efficacy for patients. This directly impacts patient outcomes and carries significant commercial implications, including potential product returns, reputational damage, and the financial burden of managing a nationwide recall. Regulatory affairs heads must ensure their organizations are fully compliant with recall procedures and are prepared to address any downstream impacts on product formulations or patient care.
Manufacturing Quality Breach: Actavis Laboratories FL Site Under Scrutiny
The recalled Budesonide Extended-Release Tablets 9mg were manufactured by Actavis Laboratories FL, Inc., located in Fort Lauderdale, Florida, and distributed by Actavis Pharma, Inc. of Parsippany, New Jersey. Both entities operate under the umbrella of Teva Pharmaceuticals USA, Inc. This incident places a direct spotlight on the manufacturing quality control processes at the Fort Lauderdale facility. For business development executives and regulatory affairs teams, this highlights the critical importance of robust supplier qualification and ongoing audit programs, particularly for contract manufacturers or subsidiaries within complex corporate structures. A failure in dissolution specifications at the manufacturing level suggests potential issues with formulation, raw material quality, or process control during tablet production. This event necessitates a thorough review of quality agreements and performance metrics for all products sourced from Actavis Laboratories FL, Inc., or any Teva-affiliated manufacturing sites. The integrity of the manufacturing process directly underpins product quality and regulatory compliance, making this a pivotal concern for any company sourcing active pharmaceutical ingredients (APIs) or finished dosage forms from these facilities.
Supply Chain Vulnerability: Impact on Budesonide Market Availability
Budesonide, a vital corticosteroid used for various inflammatory conditions, is a widely prescribed generic drug. The recall of 10,672 bottles of Budesonide Extended-Release Tablets 9mg, distributed nationwide, introduces a notable, albeit contained, vulnerability into the supply chain for this specific dosage form. While the recall is classified as Class II, indicating that use of the product may cause temporary or medically reversible adverse health consequences, the disruption can still impact patient access and create procurement challenges. For procurement directors, this event underscores the imperative of having a diversified supplier base for critical generic molecules like Budesonide. Relying on a single manufacturer or a limited number of sites for essential drugs exposes organizations to significant supply risks when quality issues arise. Supply chain VPs must assess their current inventory levels, identify any potential shortfalls, and proactively engage with alternative suppliers to ensure uninterrupted access to Budesonide. The nationwide distribution pattern means that the impact could be felt across various healthcare providers and pharmacies, potentially leading to localized shortages or increased pressure on alternative product lines.
Strategic Sourcing: Identifying Alternative Budesonide API and Finished Product Suppliers
Given the recall of Teva Pharmaceuticals' Budesonide Extended-Release Tablets 9mg, procurement teams must prioritize the identification and qualification of alternative suppliers for both Budesonide API and finished dosage forms. While specific alternative suppliers are not detailed in the provided intelligence, the generic nature of Budesonide suggests multiple manufacturers exist globally. The immediate business implication is the need to conduct a comprehensive market scan for FDA-approved or equivalent regulatory-compliant manufacturers. This process involves evaluating potential suppliers based on their regulatory history, manufacturing capabilities, quality systems, and capacity to meet demand. Qualification timelines for new pharmaceutical suppliers can be extensive, often ranging from 12 to 24 months, encompassing audits, analytical testing, and regulatory filings. Therefore, proactive engagement is crucial to mitigate long-term supply risks. Companies should also consider geographical diversity in their supplier base to reduce exposure to regional regulatory or logistical disruptions, ensuring a robust and resilient supply chain for this essential corticosteroid.
Teva Pharmaceuticals' Ongoing Regulatory Compliance Landscape
This Class II recall for Budesonide Extended-Release Tablets 9mg represents a current and significant regulatory event for Teva Pharmaceuticals USA, Inc. and its manufacturing arm, Actavis Laboratories FL, Inc. While our knowledge graph does not detail a history of prior Warning Letters or Import Alerts for Teva, any recall due to failed dissolution specifications signals a lapse in Good Manufacturing Practices (GMP) and warrants heightened scrutiny. For regulatory affairs heads and business development executives, this event reinforces the need for continuous monitoring of supplier compliance and quality performance. Organizations sourcing from Teva or its subsidiaries should consider this recall as a trigger for enhanced due diligence, potentially including more frequent supplier audits or increased incoming material testing. The FDA's ongoing classification of this recall means that the agency is actively monitoring Teva's corrective actions. Future FDA inspections at the Actavis Laboratories FL, Inc. facility are highly probable, and any further findings could escalate regulatory actions, impacting Teva's broader product portfolio and market access. Proactive engagement with Teva regarding their root cause analysis and corrective and preventive actions (CAPA) is essential for maintaining supply chain confidence.
Remediation Pathways and Future Regulatory Oversight for Teva
As a voluntary, firm-initiated recall, Teva Pharmaceuticals USA, Inc. is responsible for implementing comprehensive corrective and preventive actions (CAPA) to address the root cause of the failed dissolution specifications for Budesonide Extended-Release Tablets 9mg. The recall, initiated on January 8, 2024, and classified by the FDA on January 26, 2024, is currently ongoing. For regulatory affairs and supply chain leaders, monitoring Teva's remediation efforts is paramount. This includes evaluating the thoroughness of their root cause investigation, the effectiveness of their corrective actions, and any potential changes to their manufacturing processes or quality control systems at the Actavis Laboratories FL, Inc. facility. The FDA will maintain oversight, potentially through follow-up inspections, to verify the adequacy of Teva's response. Failure to effectively remediate the issue could lead to further regulatory actions, including additional recalls, product seizures, or even an FDA Warning Letter or Import Alert, which would severely impact Teva's ability to supply the U.S. market. Companies relying on Teva must factor these potential risks into their long-term sourcing strategies and maintain open communication channels with Teva regarding their compliance status and future product availability.